Cancer ResearchJan 07, 2021|2 min readBy DDNews StaffAvacta and POINT Biopharma pursue radiopharmaceuticalsLicense agreement allows POINT Biopharma to utilize Avacta’s pre|CISION platform for radiopharmaceuticals
